References
- Watkins EE. Yourself: consumer information about menopause and hormone replacement therapy. In Tone A, Watkins ES, editors. Medicating modern America: prescription drugs in history. New York, NY: University Press; 2007
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative memory study: a randomized controlled trial. JAMA 2003;289:2651–62
- Fishman JR, Flatt MA, Settersten RA. Jr. , Bioidentical hormones, menopausal women, and the lure of the “natural” in U.S. anti-aging medicine. Soc Sci Med 2015;132:79–87
- Fugh-Berman A, Bythrow J. Bioidentical hormones for menopausal hormone therapy: variation on a theme. J Gen Intern Med 2007;22:1030–34
- Thompson JJ, Ritenbaugh C, Nichter M. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Womens Health 2017;17:97
- Mattison DP. The clinical utility of compounded bioidentical hormone therapy: A review of safety, effectiveness, and use (Vol. Committee on the clinical utility of treating patients with compounded bioidentical hormone replacement therapy). Washington (DC): The National Academies Press; 2020
- Whelan AM, Jurgens TM, Trinacty M. Defining bioidentical hormones for menopause-related symptoms. Pharm Pract (Granada) 2011;9:16–22
- Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Womens Health (Larchmt) 2007;16:600–31
- American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; American Society for Reproductive Medicine Practice Committee. Compounded bioidentical menopausal hormone therapy. Fertil Steril 2012;98:308–12
- Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003;10:13–18
- Lee JR, Zava D. What your doctor may not tell you about breast cancer! How hormone balance can help save your life. New York (NY): Warner Books; 2002
- Lee JR, Hopkins V. What your doctor may not tell you about menopause: the breakthrough book on natural progesterone. New York (NY): Warner Books; 2004
- Sommers S. Ageless: the naked truth about bioidentical hormones (Vol. 7). New York (NY): Crown Publishers; 2006
- Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 2011;96:1642–53
- Labrie F, Martel C, Bérubé R, et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol 2013;138:359–67
- Santen RJ, Simpson E. History of estrogen: its purification, structure, synthesis, biologic actions, and clinical implications. Endocrinology 2019;160:605–25
- Rastrelli G, Guaraldi F, Reismann Y, et al. Testosterone replacement therapy for sexual symptoms. Sex Med Rev 2019;7:464–75
- La Rosa VL, Ciebiera M, Lin LT, et al. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. Prz Menopauzalny 2019;18:116–22
- Linehan JS. Drug compounding: a cause and cure for high drug prices? Pharmaceutical Executive; 2016. Available from: www.pharmexec.com
- Bradshaw MS, Tsai SY, Leng SH, et al. Studies on the mechanism of functional cooperativity between progesterone and estrogen receptors. J Biol Chem 1991;266:16684–90
- Schmidt IU, Wakley GK, Turner RT. Effects of estrogen and progesterone on tibia histomorphometry in growing rats. Calcif Tissue Int 2000;67:47–52
- Paton D. Estradiol vaginal inserts (imvexxy): effective in genitourinary syndrome of menopause without increasing systemic estrogen levels. Drugs Today (Barc) 2018;54:667–77
- Hermann AC, Nafziger AN, Victory J, et al. Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administration-approved oral progesterone product. J Clin Pharmacol 2005;45:614–19
- Pouly JL, Bassil S, Frydman R, et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contracept Fertil Sex 1997;25:596–601
- Marketplace Changes and Compounding Opportunities. An emerging HRT dosage form for women. Available from: http://tccompound.com/wp-content/uploads/2017/09/web-MOS-TC-RDT-Vaginal-Sara.pdf
- Child T, Leonard SA, Evans JS, Lass A. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod Biomed Online 2018;36:630–45
- Chi HB, Liu NN, Li R, et al. Comparison of vaginal gel and intramuscular progesterone for in vitro fertilization and embryo transfer with gonadotropin-releasing hormone antagonist protocol. Chin Med J (Engl) 2018;131:1557–61
- Ng EHU, Chan CCW, Tang OS, Ho PC. A randomized comparison of side effects and patient convenience between cyclogest suppositories and endometrin tablets used for luteal phase support in IVF treatment. Eur J Obstet Gynecol Reprod Biol 2007;131:182–8
- Saunders H, Khan C, D'Hooghe T, et al. Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial. Hum Reprod 2020;35:355–63
- Cutter C. Compounded percutaneous testosterone gel: use and effects in hypogonadal men. J Am Board Fam Pract 2001;14:22–32
- Current and Resolved Drug Shortage and Discontinuations Reported to FDA. US Food & Drug Administration; 2020. Available from: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- Section 503a of the federal food, drug, and cosmetic act. US Food & Drug Administration; 2018. Available from: https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- Caufriez A, Leproult R, L'Hermite-Balériaux M, Kerkhofs M, Copinschi G. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab 2011;96:E614
- Prometrium Product Information Label. U.S. Food & Drug Adminstration; 2009. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20843lbl.pdf
- Stevenson JC. Oral versus transdermal hormone replacement therapy. Int J Fertil Menopausal Stud 1993;38:30–5
- Goodman M. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health (Larchmt) 2012;21:161–9
- Fait T, Fialova A, Pastor Z. The use of estradiol metered-dose transdermal spray in clinical practice. Climacteric 2018;21:549–53
- Bertonazzi A, Nelson B, Salvador J, Umland E. The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis. Womens Health (Lond) 2015;11:815–24
- Egras AM, Umland EM. The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms. Int J Gen Med 2010;3:147–51
- Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2017;3:313–19
- Moegele M, Buchholz S, Seitz F, Lattrich C, Ortmann O. Vaginal estrogen therapy for patients with breast cancer. Geburtshilfe Frauenheilkd 2013;73:1017–22
- Pfeiler G, Glatz C, Konigsberg R, et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 2011;14:339–44
- Unger CA. Hormone therapy for transgender patients. Transl Androl Urol 2016;5:877–84
- De Haan G, Santos GM, Arayasirikul S, Raymond HF. Non-prescribed hormone use and barriers to care for transgender women in San Francisco. LGBT Health 2015;2:313–23
- Snyder S, Listecki RE. Bioidentical thyroid replacement therapy in practice: delivering a physiologic t4: t3 ratio for improved patient outcomes with the listecki-snyder protocol. Int J Pharm Compd 2012;16:376–80
- Madan R, Celi FS. Combination therapy for hypothyroidism: rationale, therapeutic goals, and design. Front Endocrinol (Lausanne) 2020;11:1–33
- Greene J. HRT has an uncertainty problem. Does compounding make it worse? Managed Care Magazine; 2019. Available from: https://www.managedcaremag.com/archives/2019/2/hrt-has-uncertainty-problem-does-compounding-make-it-worse
- American College of Obstetricians and Gynecologists. Journal Watch; 2014. Available from: https://www.jwatch.org/na33279/2014/01/13/new-guidance-acog-treatment-women-with-menopausal-symptoms
- Kaunitz A. American College of Obstetricians and Gynecologists. Practice Bulletin no. 141. Management of menopausal symptoms. Obstet Gynecol 2014;123:202
- Endocrine Society Position Statement. Compounded bioidentical hormone therapy. endocrine.org.; 2019. Available from: https://www.endocrine.org/advocacy/position-statements/compounded-bioidentical-hormone-therapy
- North American Menopause Society. Bioidentical hormone therapy; 2020. Available from: https://www.menopause.org/publications/clinical-practice-materials/bioidentical-hormone-therapy
- Stuenkel CA, Manson JE. Compounded bioidentical hormone therapy: does the regulatory double standard harm women? JAMA Intern Med 2017;177:1719–20
- Pastner B. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs. Food Drug Law J 2008;63:459–91
- Gabay M. The drug quality and security act. Hosp Pharm 2014;49:615–76
- Multistate outbreak of fungal meningitis and other infections. Centers for Disease Control and Prevention. CDC.gov.; 2015. Available from: http://www.cdc.gov/hai/outbreaks/meningitis.html
- Compounding Laws and Policies. US Food & Drug Adminstration; 2018. Available from: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- Compounded Sterile Preparations Pharmacy. Board of Pharmacy Specialties; n.d. Available from: https://www.bpsweb.org/bps-specialties/compounded-sterile-preparations-pharmacy/
- Compounding Standards. United States Pharmacopeia; n.d. Available from: https://www.usp.org/compounding
- USP General Chapter <795> Pharmaceutical Compouding-Nonsterile Preparations. United States Pharmacopeia; 2014. Available from: https://www.usp.org/compounding/general-chapter-795
- Graunt M. What does usp < 795> mean to you? Pharmacy Times; 2013. Available from: https://www.pharmacytimes.com/publications/issue/2013/april2013/what-does-usp-795-mean-to-you
- USP General Chapter <800> Hazardous Drugs-Handling in healthcare Settings. United States Pharmacopeia; 2017. Available from: https://www.usp.org/sites/default/files/usp/document/our-work/healthcare-quality-safety/general-chapter-800.pdf
- USP 797 Testing Lab Services. EMLab; n.d. Available from: https://www.emlab.com/services/usp-797-testing/
- GeneralChapter <797> Pharmaceutical Compounding-Sterile Preparations. Unites States Pharmacopeia; 2008. Available from: https://www.usp.org/compounding/general-chapter-797
- Compounding Pharmacy Accreditation. ACHC; 2007. Available from: https://www.achc.org/compounding-pharmacy.html
- Justenhoven C, Obazee O, Brauch H. The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy. Pharmacogenomics 2012;13:659–75
- Hass DM. Pharmacogenetics and individualizing drug treatment during pregnancy. Pharmacogenomics 2014;15:69–78
- Allen L. Jr,. Basics of compounding: 3D printing–pharmacy applications, part 1. Int J Pharm Compd 2017;21:127–30
- Allen L. Jr. Basics of compounding: 3D printing–pharmacy applications: geometric shape effects on 3D printing. Int J Pharm Compd 2017;21:388–92
- 3D printing medications arrive at pavilion compounding. Pavilion Compounding Pharmacy; 2020. Available from: https://www.pavilioncompounding.com/3d-printing-medications-pavilion-compounding-pharmacy/
- 3D Printing: Could This Be the Future of Compounding? Innovation Compounding; 2018. Available from: https://innovationcompounding.com/3d-printing-compounded-medications/
- Budholiya A. US Compounding Pharmacies Market is Expected to Reach Around US$14 Bn by the End of 2028-Future Market Insights. Globenewswire; 2019. Available from: https://www.globenewswire.com/news-release/2019/06/03/1863302/0/en/u-s-compounding-pharmacies-market-is-expected-to-reach-around-us-14-bn-by-the-end-of-2028-future-market-insights.html
- Dubaut JP, Dong F, Tjaden BL, et al. Prescribing bioidentical menopausal hormone therapy: a survey of physician views and practices. J Womens Health (Larchmt) 2018;27:859–66
- Moskowitz D. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. Altern Med Rev 2006;11:208–23
- Stephenson K, Neuenschwander PF, Kurdowska AK. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Int J Pharm Compd 2013;17:74–85
- Borda LJ, Wong LL, Tosti A. Bioidentical hormone therapy in menopause: relevance in dermatology. Dermatol Online J 2019;25:13030–38